Annual Drug Patent Expirations for VYNDAQEL
Vyndaqel is a drug marketed by Foldrx Pharms and is included in one NDA. It is available from one supplier. There are four patents protecting this drug.
Drug patent litigation for VYNDAQEL.
This drug has thirty patent family members in seventeen countries.
The generic ingredient in VYNDAQEL is tafamidis meglumine. One supplier is listed for this compound. Additional details are available on the tafamidis meglumine profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
